Albert Lowe
Stock Analyst at Craig-Hallum
(3.84)
# 1,961
Out of 4,649 analysts
139
Total ratings
42.3%
Success rate
9.5%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Maintained: Buy | $140 | $52.64 | +165.96% | 2 | Aug 13, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintained: Buy | n/a | $1.07 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | n/a | $3.61 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $156.13 | +31.30% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Maintained: Buy | $6 | $3.70 | +62.16% | 10 | Jun 16, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | $2 | $0.963 | +107.68% | 13 | Jun 4, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $36.14 | +79.86% | 7 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $25 → $12 | $1.01 | +1,088.12% | 9 | May 12, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | n/a | $2.25 | - | 6 | May 6, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.43 | $9.31 | +108.67% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.99 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.5015 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $4.60 | -13.04% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.60 | +284.62% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.54 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $13.56 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.26 | +217.46% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.58 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $325.83 | n/a | 1 | Jun 4, 2024 |
Spruce Biosciences
Aug 13, 2026
Maintained: Buy
Price Target: $140
Current: $52.64
Upside: +165.96%
Lineage Cell Therapeutics
Jul 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.07
Upside: -
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: n/a
Current: $3.61
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $156.13
Upside: +31.30%
SAB Biotherapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $6
Current: $3.70
Upside: +62.16%
Cardiff Oncology
Jun 4, 2026
Downgraded: Hold
Price Target: $2
Current: $0.963
Upside: +107.68%
Neurogene
May 15, 2026
Maintained: Buy
Price Target: $65
Current: $36.14
Upside: +79.86%
Actuate Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $25 → $12
Current: $1.01
Upside: +1,088.12%
Compass Therapeutics
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $2.25
Upside: -
Eupraxia Pharmaceuticals Inc.
May 5, 2026
Reiterated: Buy
Price Target: $19.43
Current: $9.31
Upside: +108.67%
Apr 2, 2026
Maintained: Buy
Price Target: n/a
Current: $4.99
Upside: -
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $0.5015
Upside: -
Feb 17, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $4.60
Upside: -13.04%
Feb 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Jan 23, 2026
Maintained: Buy
Price Target: n/a
Current: $3.54
Upside: -
Jan 12, 2026
Maintained: Buy
Price Target: n/a
Current: $13.56
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $4
Current: $1.26
Upside: +217.46%
Jun 6, 2024
Maintained: Buy
Price Target: n/a
Current: $9.58
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $325.83
Upside: n/a